Company: PCRX
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001628280-25-050176
Chunk: 60

Company: Pacira BioSciences, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 60
---
 fees have been allocated to the lease components based on a relative fair value basis. As part of the GQ Bio Acquisition in February 2025, the Company’s European offices were assumed and include a research and development lab and offices in Luckenwalde, Germany and administrative offices in Hamburg, Germany and each of Eupen and Liège, Belgium. The Company had been recognizing sublease income for laboratory space leased in Woburn, Massachusetts from leases that were assumed as part of the Flexion Acquisition. In February 2024, the lease and sublease term concluded for the laboratory space in Woburn and in April 2025, a lease and sublease term concluded for office space in Burlington, Massachusetts.The operating lease costs for the facilities include lease and non-lease components, such as common area maintenance and other common operating expenses, along with executory costs such as insurance and real estate taxes. Total operating lease expense, net is as follows (in thousands):Three Months EndedNine Months EndedSeptember 30,September 30,2025202420252024Fixed lease costs$3,139 $3,459 $9,673 $10,416 Variable lease costs642 562 1,757 1,345 Sublease income— (56)(76)(248)Total$3,781 $3,965 $11,354 $11,513 Supplemental cash flow information related to operating leases is as follows (in thousands):Nine Months EndedSeptember 30,20252024Cash paid for operating lease liabilities, net of lease incentives$9,650 $9,686 Right-of-use assets recorded in exchange for lease obligations$2,043 $— The Company has elected to net the amortization of the right-of-use asset and the reduction of the lease liability principal in other liabilities in the condensed consolidated statements of cash flows.The Company has measured its operating lease liabilities at an estimated discount rate at which it could borrow on a collateralized basis over the remaining term for each operating lease. The weighted average remaining lease terms and the weighted average discount rates are summarized as follows:September 30,20252024Weighted average remaining lease term4.56 years5.36 yearsWeighted average discount rate6.91 %6.99 %

Pacira BioSciences, Inc.  |  Q3 2025 Form 10-Q  |  15

Maturities of the Company’s operating lease liabilities are as